Biocon arm wins Health Canada approval for micafungin injection for deadly fungal infections

Approval also covers stem cell transplant protection

Biocon Pharma Ltd’s arm has received Health Canada approval for micafungin for injection, aimed at serious fungal infections in both adults and children. The treatment will be used for conditions such as candidemia and esophageal candidiasis, and the approval extends to prophylaxis for stem cell transplant patients. The decision adds a key new offering to Biocon’s portfolio.